Frontiers in Oncology (May 2023)

Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma

  • Sebastian Zundler,
  • Sebastian Zundler,
  • Francesco Vitali,
  • Soraya Kharboutli,
  • Simon Völkl,
  • Iris Polifka,
  • Andreas Mackensen,
  • Andreas Mackensen,
  • Raja Atreya,
  • Raja Atreya,
  • Markus F. Neurath,
  • Markus F. Neurath,
  • Dimitrios Mougiakakos,
  • Dimitrios Mougiakakos,
  • Dimitrios Mougiakakos

DOI
https://doi.org/10.3389/fonc.2023.1149450
Journal volume & issue
Vol. 13

Abstract

Read online

Chimeric antigen receptor (CAR) T cell therapy has become a new mainstay in the treatment of several hematologic malignancies, but the spectrum of associated complications is still incompletely defined. Here, we report the case of a 70-year-old female patient treated with tisagenlecleucel for diffuse large B cell lymphoma (DLBCL), who developed chronic diarrhea with characteristics of inflammatory bowel disease (IBD)-like colitis. CAR T cells were substantially enriched in the colon lamina propria and other diagnoses were ruled out. Thus, we conclude that IBD-like colitis in this patient was associated to CAR T cell therapy and needs to be considered as a rare potential complication.

Keywords